Table of Contents
| << Previous Issue | Feb 2025 (Vol: 2025, Issue: 2) | Next Issue >> |
- Section: Mergers & Acquisitions
-
GSK Pays US$1.15 B To Acquire IDRx
-
Novartis Regains Abelacimab Through US$3.1 B Acquisition of Anthos Therapeutics
- Section: Research & Development
-
AbbVie Signs Immuno-Oncology Partnership with Neomorph for US$1.64 B
-
AbbVie Collaborates with Xilio Therapeutics to Develop Antibody-Based Immunotherapies
-
Incyte and Genesis Therapeutics Sign US$620 M AI-focused Collaboration



RSS